ATM and melanoma: Also, phase II clinical trials checking the efficacy of PARPi treatment in patients with cancer with among others somatic or germline ATM gene mutations, are currently underway (NCT04042831, NCT03344965, NCT02286687, NCT04030559), even for patients with melanoma (NCT03925350, NCT04633902).